Ligand Stock: Expanding Royalty Portfolio And Strong Drug Pipeline (NASDAQ:LGND)

0

Sean Anthony Eddy

Ligand Pharmaceuticals (NASDAQ:LGND) has built an impressive portfolio of drugs and technologies for the treatment of a range of medical conditions. Its sector-leading drugs like Filspari have shown significant improvement in clinical outcomes for patients, setting the

2023 outlook

investor.ligand.com

royalty table

ligand.com

current portfolio

investor.ligand.com

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Please enter CoinGecko Free Api Key to get this plugin works.